Literature DB >> 16522777

Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.

Isabelle Henckaerts1, David Goldblatt, Lindsey Ashton, Jan Poolman.   

Abstract

A comparative study was conducted between two laboratories in order to evaluate the differences between two enzyme-linked immunosorbent assay (ELISA) techniques for the detection of pneumococcal anti-capsular polysaccharide antibodies. One laboratory used an assay including heterologous 22F polysaccharide inhibition, and the other laboratory employed a non-22F reference assay. After conjugate immunization, 30 pediatric post-primary immunization sera with antipolysaccharide concentrations ranging from <0.05 to 15 mug/ml were analyzed. Aggregate reverse cumulative distribution curves combining concentrations of antibodies against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F revealed similar results for both methods at antibody levels of >1 microg/ml. However, at antibody levels of <1 microg/ml, the distribution curve measured with the 22F inhibition ELISA shifted toward lower levels. This observation suggests that the 22F inhibition assay is more specific at low antibody concentrations, which was confirmed by heterologous polysaccharide inhibition experiments. Translation of low antibody levels suggested that the proposed threshold concentration of 0.35 mug/ml determined with the non-22F ELISA corresponded to a concentration of 0.20 mug/ml with the 22F inhibition ELISA. Pneumococcal antipolysaccharide ELISA including 22F inhibition can be recommended as a reference method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522777      PMCID: PMC1391962          DOI: 10.1128/CVI.13.3.356-360.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  11 in total

Review 1.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae.

Authors:  T Kelly; J P Dillard; J Yother
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.

Authors:  S A Quataert; C S Kirch; L J Wiedl; D C Phipps; S Strohmeyer; C O Cimino; J Skuse; D V Madore
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

6.  The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data.

Authors:  G F Reed; B D Meade; M C Steinhoff
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

7.  Effects of absorption with pneumococcal type 22F polysaccharide on maternal, cord blood, and infant immunoglobulin G antipneumococcal polysaccharide antibodies.

Authors:  J Inostroza; S Villanueva; K Mason; L E Leiva; R U Sorensen
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

8.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

9.  Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.

Authors:  Daniel R Feikin; Cheryl M Elie; Matthew B Goetz; Jeffrey L Lennox; George M Carlone; Sandra Romero-Steiner; Patricia F Holder; William A O'Brien; Cynthia G Whitney; Jay C Butler; Robert F Breiman
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

10.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.

Authors:  Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

View more
  32 in total

Review 1.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

2.  Measurement of pneumococcal polysaccharide antibodies.

Authors:  Ricardo U Sorensen; Lily E Leiva
Journal:  J Clin Immunol       Date:  2013-12-17       Impact factor: 8.317

3.  Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.

Authors:  Johanna Karlsson; Lucy Roalfe; Harriet Hogevik; Marta Zancolli; Björn Andréasson; David Goldblatt; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 4.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

5.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

6.  Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Authors:  Jan Poolman; Carl Frasch; Anu Nurkka; Helena Käyhty; Ralph Biemans; Lode Schuerman
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

7.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

Review 8.  New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

Authors:  R Ameratunga; S-T Woon; D Gillis; W Koopmans; R Steele
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

9.  Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease.

Authors:  Tomohiro Oishi; Naruhiko Ishiwada; Kousaku Matsubara; Junichiro Nishi; Bin Chang; Kazuyo Tamura; Yukihiro Akeda; Toshiaki Ihara; Moon H Nahm; Kazunori Oishi
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

10.  Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Authors:  Birgit Simell; Mika Lahdenkari; Antti Reunanen; Helena Käyhty; Merja Väkeväinen
Journal:  Clin Vaccine Immunol       Date:  2008-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.